Inhibiting colorectal carcinoma growth and metastasis by blocking the expression of VEGF using RNA interference

Neoplasia

Volumn 10, Issue 4, 2008, Pages 399-407

  Wang, Shaochuang ^a   Liu, Hui ^b   Ren, Lifeng ^a   Pan, Yifeng ^a   Zhang, Yangde ^a,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c NONE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SMALL INTERFERING RNA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; METASTASIS; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR GROWTH;

EID: 41649105281     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07613     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, and Thun J (2007). Cancer statistics, 2007. CA Cancer J Clin 57, 43-66.
2. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, and Ferrara N (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306-1309.
3. Takahashi Y, Bucana CD, Liu W, Yoneda J, Kitadai Y, Cleary KR, and Ellis LM (1996). Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 88, 1146-1151.
4. Volm M, Koomägi R, Mattern J, and Stammler G (1997). Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro. Anticancer Res 17, 99-103.
5. Yoshiji H, Gomez DE, Shibuya M, and Thorgeirsson UP (1996). Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 56, 2013-2016.
6. Ferrara N and Davis-Smyth T (1997). The biology of vascular endothelial growth factor. Endocr Rev 18, 4-25.
7. Suzuki K, Hayashi N, Miyamoto Y, Yamamoto M, Ohkawa K, Ito Y, Sasaki Y, Yamaguchi Y, Nakase H, Noda K, et al. (1996). Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res 56, 3004-3009.
8. Ellis LM, Takahashi Y, Fenoglio CJ, Cleary KR, Bucana CD, and Evans DB (1998). Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur J Cancer 34, 337-340.
9. Uchida S, Shimada Y, Watanabe G, Tanaka H, Shibagaki I, Miyahara T, Ishigami S, and Imamura M (1998). In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br J Cancer 77, 1704-1709.
10. Tomisawa M, Tokunaga T, Oshika Y, Tsuchida T, Fukushima Y, Sato H, Kijima H, Yamazaki H, Ueyama Y, Tamaoki N, et al. (1999). Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer 35, 133-137.
11. Sowter HM, Corps AN, and Evans AL (1997). Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab Invest 77, 607-614.
12. Guidi AJ, Abu-Jawdeh G, Tognazzi K, Dvorak HF, and Brown LF (1996). Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer 78, 454-460.
13. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, and Tuschl T (2001). Duplexes of 21-nucleotide RNAs mediate interference in cultured mammalian cells. Nature (Lond) 411, 494-498.
14. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, and Mello CC (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (Lond) 391, 806-811.
15. Detwiller KY, Fernando NT, Segal NH, Ryeom SW, D'Amore PA, and Yoon SS (2005). Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. Cancer Res 65, 5881-5889.
16. Guan H, Zhou ZC, Wang H, Jia SF, Liu W, and Kleinerman ES (2005). A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin Cancer Res 11, 2662-2669.
17. Elbashir SM, Harborth J, Weber K, and Tuschl T (2002). Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26, 199-213.
18. Burfeind P, Chernicky CL, Rininsland F, and Ilan J (1996). Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 93, 7263-7268.
19. Long L, Rubin R, and Brodt P (1998). Increased invasive and metastatic potential in tumor cells overexpressing the receptor for type 1 insulin-like growth factor receptor. Exp Cell Res 238, 116-121.
20. Takei Y, Kadomatsu K, Matsuo S, Itoh H, Nakazawa K, Kubota S, and Muramatsu T (2001). Antisense oligodeoxynucleotide targeted to midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res 61, 8486-8491.
21. Park YW, Younes MN, Jasser SA, Yigitbasi OG, Zhou G, Bucana CD, Bekele BN, and Myers JN (2005). AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice. Clin Cancer Res 11, 1963-1973 [March 1].
22. Ohta Y, Endo Y, Tanaka M, Shimizu J, Oda M, Hayashi Y, Watanabe Y, and Sasaki T (1996). Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 2, 1411-1416.
23. Guerrin M, Moukadiri H, Chollet P, Moro F, Dutt K, Malecaze F, and Plouët J (1995). Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro. J Cell Physiol 164, 385-394.
24. Oberg-Welsh C, Sandler S, Andersson A, and Welsh M (1997). Effects of vascular endothelial growth factor on pancreatic duct cell replication and the insulin production of fetal islet-like cell clusters in vitro. Mol Cell Endocrinol 126, 125-132.
25. Sondell M, Lundborg G, and Kanje M (1999). Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 19, 5731-5740.
26. Kranz A, Mattfeldt T, and Waltenberger J (1999). Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Int J Cancer 84, 293-298.
27. Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, Robinson G, and Mercurio AM (2001). Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 61, 5736-5740.
28. Nakopoulou L, Stefanaki K, Panayotopoulou E, Giannopoulou I, Athanassiadou P, Gakiopoulou-Givalou H, and Louvrou A (2002). Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation. Hum Pathol 33, 863-870.
29. Soker S, Kaefer M, Johnson M, Klagsbrun M, Atala A, and Freeman MR (2001). Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. Am J Pathol 159, 651-659.
30. Jackson MW, Roberts JS, Heckford SE, Ricciardelli C, Stahl J, Choong C, Horsfall DJ, and Tilley WD (2002). A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 62, 854-859.
31. Tian X, Song SM, Wu J, Meng L, Dong Z, and Shou C (2001). Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803. Biochem Biophys Res Commun 286, 505-512.
32. Kim SJ, Seo JH, Lee YJ, Yoon JH, Choi CW, Kim BS, Shin SW, Kim YH, and Kim JS (2005). Autocrine vascular endothelial growth factor/vascular endothelial growth factor receptor-2 growth pathway represents a cyclooxygenase-independent target for the cyclooxygenase-2 inhibitor NS-398 in colon cancer cells. Oncology 68, 204-211.
33. Viloria-Petit A, Miquerol L, Yu JL, Gertsenstein M, Sheehan C, May L, Henkin J, Lobe C, Nagy A, Kerbel RS, et al. (2003). Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. EMBO J 22, 4091-4102.
34. Duxbury MS and Whang EE (2004). RNA interference: a practical approach. J Surg Res 117, 339-344.
35. Dave RS and Pomerantz RJ (2003). RNA interference: on the road to an alternate therapeutic strategy! Rev Med Virol 13, 373-385.
36. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu PY, Scaria PV, and Woodle MC (2004). Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32, e149.
37. Brummelkamp TR, Bernards R, and Agami R (2002). Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2, 243-247.
38. Wilda M, Fuchs U, Wössmann W, and Borkhardt A (2002). Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 21, 5716-5724.